
BONESUPPORT Q2 - Strong development, but more leg room for the share

Redeye sees that BONESUPPORT is well-equipped to surpass its new 50% 2024e sales growth target, and we positively reconsider our US CERAMENT G open trauma sales rampup. Despite a lower-than-expected EBIT, the coming quarters should allow the company to demonstrate its excellent operating leverage more clearly. We up our fair value range somewhat.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[BONESUPPORT Q2 - Strong development, but more leg room for the share](#)